CDC/HRSA Advisory Committee on HIV and STD Prevention and Treatment, 13288 [07-1374]
Download as PDF
<![CDATA[
13288
Federal Register / Vol. 72, No. 54 / Wednesday, March 21, 2007 / Notices
the agreement and proposed order or to
modify in any way their terms.
Prevention and the Agency for Toxic
Substances and Disease Registry.
By direction of the Commission.
Donald S. Clark,
Secretary.
[FR Doc. 07–1403 Filed 3–20–07; 8:45 am]
Dated: March 14, 2007.
Elaine L. Baker,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. 07–1374 Filed 3–20–07; 8:45 am]
BILLING CODE 6750–01–P
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Food and Drug Administration
jlentini on PROD1PC65 with NOTICES
CDC/HRSA Advisory Committee on
HIV and STD Prevention and Treatment
In accordance with section l0(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention and the Health
Resources and Services Administration
announce the following meeting of the
aforementioned committee.
Times and Dates: 8 a.m. – 5 p.m., May
7, 2007. 8 a.m. – 12:30 p.m., May 8,
2007.
Place: Embassy Suites Hotel Atlanta
Buckhead, 3285 Peachtree Road, NE.,
Atlanta, Georgia, Telephone 404/261–
7733, Fax 404/262–0522.
Status: Open to the public, limited
only by the space available. The meeting
room will accommodate approximately
100 people.
Purpose: This Committee is charged
with advising the Director, CDC and the
Administrator, HRSA, regarding
activities related to prevention and
control of HIV/AIDS and other STDs,
the support of health care services to
persons living with HIV/AIDS, and
education of health professionals and
the public about HIV/AIDS and other
STDs.
Matters To Be Discussed: Agenda
items include issues pertaining to (1)
Priorities for STD Prevention (2) HIV
Strategic Plan Implementation and (3)
Leveraging Federal Partnerships for
HIV/STD Prevention. Agenda items are
subject to change as priorities dictate.
Contact Person for More Information:
Margie Scott-Cseh, Committee
Management Specialist, National Center
for HIV, STD, and TB Prevention, 1600
Clifton Road, NE., Mailstop E–07,
Atlanta, Georgia 30333. Telephone 404/
639–8317, Fax 404/639–8600, e-mail
zkr7@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
Notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
VerDate Aug<31>2005
17:08 Mar 20, 2007
Jkt 211001
Medical Devices Dispute Resolution
Panel of the Medical Devices Advisory
Committee; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Medical Devices
Dispute Resolution Panel of the Medical
Devices Advisory Committee.
General Function of the Committee:
To provide advice and
recommendations to the agency on
scientific disputes between the Center
for Devices and Radiological Health and
sponsors, applicants, and
manufacturers.
Date and Time: The meeting will be
held on April 19, 2007, from 8:30 a.m.
to 5:30 p.m.
Location: Holiday Inn, Ballroom, Two
Montgomery Village Ave., Gaithersburg,
MD.
Contact Person: Nancy Collazo-Braier,
Center for Devices and Radiological
Health (HFZ–1), Food and Drug
Administration, 9200 Corporate Blvd.,
Rockville, MD 20850, 240–276–3959, email: nancy.braier@fda.hhs.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area), code
3014510232. Please call the Information
Line for up-to-date information on this
meeting.
Agenda: The committee will discuss,
make recommendations, and vote
regarding a scientific dispute between
the agency and Cardima Inc. related to
the not-approvable determination for
the premarket approval application
(PMA) for the REVELATION Tx
Microcatheter with NavAblator Ablation
System, indicated for the treatment of
drug refractory paroxysmal atrial
fibrillation.
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
FDA intends to make background
material available to the public no later
than 1 business day before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/ohrms/
dockets/ac/acmenu.htm, click on the
year 2007 and scroll down to the
appropriate advisory committee link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before April 5, 2007. Oral
presentations from the public will be
scheduled between approximately 9
a.m. and 9:30 a.m. and between
approximately 1:30 p.m. and 2 p.m.
Those desiring to make formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before March
28, 2007. Time allotted for each
presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by March 29, 2007.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Ann Marie
Williams, Conference Management
Staff, at 301–827–7291, at least 7 days
in advance of the meeting.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
E:\FR\FM\21MRN1.SGM
21MRN1
]]>Agencies
[Federal Register Volume 72, Number 54 (Wednesday, March 21, 2007)]
[Notices]
[Page 13288]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-1374]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
CDC/HRSA Advisory Committee on HIV and STD Prevention and
Treatment
In accordance with section l0(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention and the Health Resources and Services Administration
announce the following meeting of the aforementioned committee.
Times and Dates: 8 a.m. - 5 p.m., May 7, 2007. 8 a.m. - 12:30 p.m.,
May 8, 2007.
Place: Embassy Suites Hotel Atlanta Buckhead, 3285 Peachtree Road,
NE., Atlanta, Georgia, Telephone 404/261-7733, Fax 404/262-0522.
Status: Open to the public, limited only by the space available.
The meeting room will accommodate approximately 100 people.
Purpose: This Committee is charged with advising the Director, CDC
and the Administrator, HRSA, regarding activities related to prevention
and control of HIV/AIDS and other STDs, the support of health care
services to persons living with HIV/AIDS, and education of health
professionals and the public about HIV/AIDS and other STDs.
Matters To Be Discussed: Agenda items include issues pertaining to
(1) Priorities for STD Prevention (2) HIV Strategic Plan Implementation
and (3) Leveraging Federal Partnerships for HIV/STD Prevention. Agenda
items are subject to change as priorities dictate.
Contact Person for More Information: Margie Scott-Cseh, Committee
Management Specialist, National Center for HIV, STD, and TB Prevention,
1600 Clifton Road, NE., Mailstop E-07, Atlanta, Georgia 30333.
Telephone 404/639-8317, Fax 404/639-8600, e-mail zkr7@cdc.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register Notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Dated: March 14, 2007.
Elaine L. Baker,
Acting Director, Management Analysis and Services Office, Centers for
Disease Control and Prevention.
[FR Doc. 07-1374 Filed 3-20-07; 8:45 am]
BILLING CODE 4163-18-P
